FNBP1L (Center), 349-377 Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-FNBP1L (Center), 349-377 antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityFNBP1L (Center), 349-377
Clonepolyclonal
Host SpeciesRabbit
Reactive Specieshuman, mouse (predicted reactivity: rat)
Isotypen/a
Formatpeptide affinity purified
Size0.08 mL, 0.4 mL
Concentrationvial concentration: 0.39
ApplicationsWestern Blot (WB), ELISA (EIA)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionThis FNBP1L antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 349-377 amino acids from the Central region of human FNBP1L. The protein encoded by this gene binds to both CDC42 andN-WASP. This protein promotes CDC42-induced actin polymerization byactivating the N-WASP-WIP complex and, therefore, is involved in apathway that links cell surface signals to the actin cytoskeleton.Alternative splicing results in multiple transcript variantsencoding different isoforms.
Immunogenn/a
Other Names[Formin-binding protein 1-like; Transducer of Cdc42-dependent actin assembly protein 1; Toca-1; FNBP1L; C1orf39; TOCA1]
Gene, Accession #[FNBP1L], Gene ID: 54874, NCBI: NP_001020119.1, UniProt: Q5T0N5
Catalog #MBS9203429
Price$165, $370
Order / More InfoFNBP1L (Center), 349-377 Antibody from MYBIOSOURCE INC.
Product Specific ReferencesRose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) : Bu, W., et al. PLoS ONE 5 (8), E12153 (2010) : Bu, W., et al. J. Biol. Chem. 284(17):11622-11636(2009) Huett, A., et al. J. Immunol. 182(8):4917-4930(2009) Leung, Y., et al. Cell Host Microbe 3(1):39-47(2008)
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.